Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 12/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | F11 | P03951 | 1/20 | 0.30 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4263307 | 0.89 | LPL (0.34) | LPLLIPG | |
| SCHEMBL120211 | 0.85 | LPL (0.42) | LPLLIPGP2RX7CA1CA2 | |
| SCHEMBL390494 | 0.79 | LPL (0.40) | LPLLIPGP2RX7CA1CA2 | |
| SCHEMBL30846 | 0.78 | LPL (0.37) | LPLLIPGP2RX7CA1CA2 | |
| SCHEMBL5892452 | 0.76 | LPL (0.36) | LPLLIPGP2RX7CA1CA2 | |
| SCHEMBL14854211 | 0.76 | LPL (0.36) | LPLLIPGP2RX7CA1CA2 | |
| SCHEMBL28587337 | 0.76 | LPL (0.36) | LPLLIPGP2RX7CA1CA2 | |
| SCHEMBL16001682 | 0.76 | LPL (0.36) | LPLLIPGP2RX7CA1CA2 | |
| SCHEMBL14332445 | 0.76 | LPL (0.43) | LPLLIPGP2RX7CA1CA2 | |
| SCHEMBL28580669 | 0.74 | LPL (0.41) | LPLLIPGP2RX7CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116253755-A | Synthesis method of diaryl borate compound | 湖南大学 | 2023-06-13 | — | — | CN | claimed |
| CN-109942572-B | V-type organic dye sensitizer and preparation method and application thereof | 南京邮电大学 | 2021-08-10 | — | — | CN | claimed |
| CN-116253755-A | Synthesis method of diaryl borate compound | 湖南大学 | 2023-06-13 | — | — | CN | disclosed |
| CN-109942572-B | V-type organic dye sensitizer and preparation method and application thereof | 南京邮电大学 | 2021-08-10 | — | — | CN | disclosed |
| EP-2545058-B1 | TETRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS INHIBITORS OF HISTAMINE RECEPTORS | KALYPSYS INC (US) | 2016-08-24 | — | — | EP | disclosed |
| US-8569300-B2 | Substituted tetrazolo[1,5-A]pyrazine inhibitors of histamine receptors for the treatment of disease | KALYPSYS INC. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2545058-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | Kalypsys, Inc. (US) | 2013-01-16 | — | — | EP | disclosed |
| US-20110237565-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| WO-2011112766-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| EP-2110398-A1 | METHOD FOR PRODUCING STRUCTURE WHEREIN AROMATIC POLYMER IS BONDED TO BASE, STRUCTURE HAVING AROMATIC POLYMER CHAIN BONDED TO CONDUCTIVE BASE, AND ELECTRONIC DEVICE COMPRISING THE STRUCTURE | Sumitomo Chemical Company, Limited (JP) | 2009-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237565-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | LPL 4837/4885LIPG 3888/4885P2RX7 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.